Insulin Market Size & Share 2026-2035

Insulin Market Size

The global insulin market was valued at USD 29.2 billion in 2025 and is projected to increase from USD 30.7 billion in 2026 to USD 41.4 billion by 2035, reflecting a 3.4% CAGR.

Demand is anchored in a therapeutic category where treatment cannot be deferred for people with type 1 diabetes and often becomes necessary as type 2 diabetes progresses beyond non-insulin treatment.

The epidemiological base continues to widen. The International Diabetes Federation estimated that 537 million adults aged 20–79 were living with diabetes in 2021, with the total projected to reach 643 million by 2030 and 783 million by 2045; it also estimated that 45% of adults with diabetes were undiagnosed. Separately, NCD Risk Factor Collaboration estimated that more than one billion people were living with obesity in 2022, including 879 million adults and 159 million children and adolescents. The overlap between obesity, insulin resistance, delayed diagnosis, and progressive beta-cell dysfunction expands the future pool of patients likely to require insulin escalation. ^{[1]International Diabetes Federation — idf.org}

Insulin analog generated USD 22.3 billion in 2025 and remains the commercial center of the market. Its value reflects the premium placed on formulations designed to alter onset, duration, or peak activity relative to conventional human insulin. Novo Nordisk, Eli Lilly, and Sanofi together account for more than 90% of market value. Their position rests on biologics manufacturing know-how, established device ecosystems, broad regulatory portfolios, and deep formulary relationships, although biosimilar approvals are progressively opening selected product classes to substitution. ^{[2]NCD Risk Factor Collaboration / The Lancet — pubmed.ncbi.nlm.nih.gov}

In the United States, 38.4 million people had diabetes in 2021, including 8.7 million undiagnosed cases. The country accounted for USD 10.6 billion of insulin revenue in 2025, illustrating the effect of high analog penetration and historically elevated list prices. Patient volume alone, however, does not determine market value: tender systems, reimbursement coverage, biosimilar substitution rules, and domestic manufacturing policies create sharply different revenue pools across regions.

Value capture will remain more concentrated than patient demand. A three-company group controlling more than 90% of market value can defend substantial portions of the analog pool through manufacturing scale, device compatibility, regulatory reach, and payer contracting. The primary commercial risk is therefore not a collapse in clinical need; it is a redistribution of value as biosimilars, public procurement, and affordability policies lower realized prices in products where treatment continuity permits switching. Suppliers able to pair dependable supply with lower-cost analog access are better positioned than those relying solely on legacy list-price architecture.

Key Drivers

Diabetes Burden, Diagnosis, and Treatment Escalation

Diabetes prevalence creates the market's underlying volume requirement, but diagnosis and disease progression determine when that requirement converts into insulin use. The IDF projects a 46% increase in adults living with diabetes between 2021 and 2045, exceeding the expected growth of the global population over the same period. The large undiagnosed population represents an access and public-health challenge, but it also indicates that measured insulin demand understates the eventual treatment need in countries improving screening and chronic-disease management. ^{[3]National Institute of Diabetes and Digestive and Kidney Diseases — niddk.nih.gov}

Type 1 diabetes provides the most durable demand layer because endogenous insulin production is insufficient. The IDF T1D Index estimated that 1.8 million children and adolescents under age 20 were living with type 1 diabetes in 2025, while the global population across all ages is projected to reach 14.7 million by 2040. This population requires uninterrupted treatment, favoring suppliers and distribution channels that can ensure dependable availability rather than merely low unit prices.

Gestational diabetes adds a separate, time-bound demand stream. An estimated one in six live births was affected by hyperglycemia in pregnancy in 2021, with gestational diabetes accounting for most cases. Insulin remains an established pharmacological option when nutrition and lifestyle measures do not achieve glycemic control because it does not cross the placenta. Higher maternal age and obesity can therefore influence both immediate pregnancy-related insulin use and longer-term type 2 diabetes risk.

Connected Delivery and Precision Dosing

Connected pens, continuous glucose monitors, pumps, and automated insulin delivery systems are changing the commercial value of insulin from a stand-alone molecule toward a component of a managed treatment system. Connected pen technology can record dose history, support dose calculations, and identify missed doses, addressing adherence gaps in multiple-daily-injection regimens. The practical consequence is not simply more digital engagement; better dose visibility can reinforce persistence with prescribed insulin and make high-value analog regimens more manageable outside specialist settings.

Automated insulin delivery has particular relevance for rapid-acting analogs because closed-loop systems adjust delivery in response to glucose readings. The FDA authorized CamAPS FX for people with type 1 diabetes aged two years and older in May 2024. Insulet reported that its SECURE-T2D pivotal trial supported expanded use of Omnipod 5 in type 2 diabetes, broadening the addressable population for automated delivery beyond the traditional type 1 diabetes base. Adoption will depend on reimbursement, training, and device availability, but the systems strengthen demand for rapid-acting formulations where technology use is clinically and economically supported. ^{[4]Capital Region of Denmark Research Portal — research.regionh.dk}

Affordability Measures and Public-Sector Procurement

Policy is shaping insulin demand and pricing simultaneously. The Inflation Reduction Act capped Medicare Part D patient out-of-pocket spending for covered insulin products at USD 35 per month, while the INSULIN Act and Affordable Insulin Now Act propose broader affordability provisions. Eli Lilly announced in March 2023 that it would reduce the list prices of Humalog and Humulin by 70% and expand its insulin affordability program. These measures can improve continuity of therapy for patients exposed to high out-of-pocket costs, even as they reduce the pricing headroom available to originator manufacturers.

In emerging markets, insulin growth is more closely linked to procurement design and supply-chain execution. Centralized tenders can broaden access by converting large patient populations into treated populations, but they also transfer bargaining power to public purchasers. Suppliers seeking volume in these settings must compete on local registration, reliable cold-chain supply, packaging, and tender economics, rather than on the premium product positioning that sustains analog value in the U.S. and selected European markets. ^{[5]International Diabetes Federation (GDM) — europepmc.org}

Key Restraints

Affordability, Reimbursement, and Supply Continuity

Insulin remains unaffordable for many patients despite its long clinical history. The IDF estimated global diabetes-related health expenditure at USD 966 billion in 2021. High aggregate spending does not ensure consistent access, particularly where insurance coverage is limited, public purchasing budgets are constrained, or temperature-controlled distribution is unreliable. In these markets, product availability can be interrupted even when clinical demand is acute.

The pricing issue is especially consequential in the U.S. because list prices, rebates, benefit design, and pharmacy access have historically produced different patient costs for the same insulin. Lilly's 2023 price reductions illustrate the pressure on manufacturers to respond, but lower list prices do not automatically eliminate coverage restrictions, formulary switching, or administrative barriers. The result is a market in which pricing reform can increase volume and adherence while constraining revenue per unit.

Non-Insulin Options in Type 2 Diabetes

Non-insulin therapies can delay the point at which some people with type 2 diabetes begin basal insulin. This pressure is concentrated in earlier treatment escalation, where clinicians may select therapies offering glycemic control with weight-loss, cardiovascular, or renal benefits. It does not remove insulin's role for patients with advanced beta-cell failure, acute metabolic decompensation, pregnancy-related indications, or type 1 diabetes. ^{[6]StatPearls Publishing — ncbi.nlm.nih.gov}

The restraint is therefore selective rather than market-wide. Type 1 diabetes accounted for 75.2% of market value in 2025 and has no substitute for exogenous insulin. For type 2 diabetes, non-insulin treatments may alter the timing and intensity of insulin initiation, but longer disease duration and deteriorating insulin secretion still preserve substantial demand for basal and basal-bolus therapy. Manufacturers face a more material risk in mix and treatment sequencing than in the elimination of insulin use.

The market remains insulated from a simple price-volume downturn because type 1 diabetes represented 75.2% of market value in 2025 and requires lifelong insulin treatment. Pressure from non-insulin type 2 diabetes therapies is concentrated in treatment sequencing and may slow basal-insulin initiation for selected patients, but it does not replace insulin for people with advanced disease. The strategic challenge is to protect access, device compatibility, and supply reliability while adapting to lower net prices and more assertive payer control.

Global Insulin Market Segment Analysis

By Type

Human insulin and insulin analog serve distinct clinical and economic roles. Insulin analog generated USD 22.3 billion in 2025, reflecting the value placed on formulations with more predictable timing profiles and compatibility with modern delivery systems. In high-income markets, analog use is closely tied to reimbursement, pen adoption, and automated delivery. Human insulin remains important where affordability, established prescribing practice, and public procurement favor lower-cost options. ^{[7]Diabetes Spectrum — pmc.ncbi.nlm.nih.gov}

The main competitive transition is not a binary displacement of human insulin by analogs. Biosimilar analogs increasingly allow purchasers to seek analog pharmacokinetics at lower prices, putting pressure on originator products while narrowing the historical clinical-economic divide between human and analog insulin. The FDA's February 2025 approval of Merilog as the first rapid-acting insulin biosimilar in the U.S. extends that transition beyond the long-acting category.

By Product

Long-acting insulin held 45.3% of market value in 2025. Its scale reflects the central role of basal coverage across both type 1 and type 2 diabetes, as well as its use as the typical initial insulin regimen for many people with progressive type 2 diabetes. Because long-acting products are used chronically and commonly appear on formularies, they are particularly exposed to biosimilar substitution and payer-driven switching. ^{[8]University of Cambridge — cam.ac.uk}

Rapid-acting insulin accounted for 31.3% of revenue in 2025. Demand is reinforced by basal-bolus regimens and by automated insulin delivery systems, which use rapid-acting formulations to make frequent algorithm-driven adjustments. Merilog's approval is commercially significant because it introduces biosimilar competition into a product category that is central to intensive therapy and device-enabled care.

Combination insulin supports simpler dosing schedules for patients who may not be able to manage a full basal-bolus regimen. Its relevance is often greater in settings where clinical follow-up is limited and fixed-ratio products reduce regimen complexity. The biosimilar sub-segment is becoming the principal vehicle for price competition across established analog categories. Other products, including inhaled insulin and specialized formulations, remain more selective in use and depend on clearly differentiated patient or delivery needs.

By Application

Type 1 diabetes mellitus represented 75.2% of market value in 2025 and is projected to grow at a 3.3% CAGR through 2035. The segment commands disproportionate value because treatment is continuous, intensive regimens commonly require both basal and mealtime insulin, and users may benefit from analogs, pens, pumps, and automated delivery systems. Its demand profile is less sensitive to changes in non-insulin treatment guidelines than type 2 diabetes.

Type 2 diabetes mellitus is projected to grow at a faster 3.9% CAGR. The rate reflects a larger and growing patient population, later diagnosis in many countries, and treatment progression when oral or non-insulin injectable therapies no longer provide adequate glycemic control. Its commercial profile is less predictable than type 1 diabetes because prescribers can adjust the timing, type, and intensity of insulin therapy in response to patient comorbidities, affordability, and competing treatments. ^{[9]Insulet Corporation — businesswire.com}

Gestational diabetes is a smaller segment, but it has distinct clinical requirements. When pharmacological treatment is required during pregnancy, insulin's inability to cross the placenta supports its clinical role. Regional variation in screening, diagnostic thresholds, antenatal care, and access to specialist treatment creates a more fragmented commercial environment than in chronic type 1 diabetes care.

By Distribution Channel

Hospital pharmacies are the leading distribution channel and are projected to reach USD 21.5 billion by 2035. Their position reflects the importance of hospital-affiliated clinicians in insulin initiation, titration, acute-care management, and treatment of complex diabetes. In publicly funded systems, hospitals also serve as purchasing and dispensing nodes for tendered insulin, concentrating commercial decisions at the institutional level. ^{[10]U.S. Congress (INSULIN Act) — congress.gov}

Retail pharmacies remain essential for long-term outpatient refills, particularly in markets where chronic medicines are accessed through reimbursed prescriptions. Their role becomes more consequential as biosimilar substitution expands because product switches often occur through formulary decisions and pharmacy-level dispensing practices.

Online pharmacies represent a developing route for recurring prescriptions where telehealth, electronic prescribing, reimbursement, and temperature-controlled delivery are sufficiently mature. The channel is constrained by the need to preserve product integrity in transit and by differing regulations governing prescription fulfillment. Its growth therefore depends less on consumer convenience alone than on the ability to integrate logistics, clinical oversight, and payment systems.

Type 1 diabetes supplies the market's most dependable value base, with a 75.2% share in 2025, while type 2 diabetes delivers the faster 3.9% growth rate. This divergence matters because it separates stable, high-intensity treatment demand from the larger but more treatment-pathway-sensitive population. Hospital pharmacies reaching USD 21.5 billion by 2035 further indicate that insulin commercialization is still shaped heavily by institutional reimbursement, clinician-led initiation, and procurement. Winning suppliers will need to secure channel access as deliberately as product preference.

Global Insulin Market Regional Analysis

North America

North America accounted for 40.1% of global insulin revenue in 2025, and the U.S. market was valued at USD 10.6 billion. High analog penetration, broad use of insulin pens and pumps, and established specialist care support market value, while affordability reform and biosimilar entry are reshaping the revenue model. The U.S. recorded 38.4 million people with diabetes in 2021, including 8.7 million undiagnosed cases.

The U.S. combines substantial clinical demand with unusually active price intervention. Medicare's USD 35 monthly insulin cap and manufacturer price reductions are narrowing the gap between list-price practices and patient affordability. Canada contributes a more reimbursement-led environment, where biosimilar formulary decisions can influence product selection. Across the region, manufacturers must manage substitution risk while maintaining continuity for patients using specific pens, pumps, or automated delivery systems.

Europe

Europe is projected to grow at a 3.7% CAGR through 2035. Germany, the UK, France, Italy, Spain, and the Netherlands are shaped by mature reimbursement systems, national health technology assessment, and greater purchaser willingness to use biosimilars where clinical continuity can be maintained. The region's large type 1 diabetes population and technology-enabled diabetes care support demand for analog and device-compatible formulations.

Germany is a major market because its statutory insurance system creates broad access but also strengthens payer leverage in formulary negotiations. The UK, France, Italy, Spain, and the Netherlands each combine established specialist care with distinct national procurement and reimbursement mechanisms. Consequently, product adoption depends on local formularies and tendering practices, rather than a single European pricing model.

Asia Pacific

Asia Pacific contains the largest concentration of people living with diabetes. China is central to the region's commercial outlook because of its large patient population and use of volume-based procurement, which rewards domestic manufacturing scale and competitive tender pricing. Gan & Lee Pharmaceuticals and Tonghua Dongbao Pharmaceutical are positioned to benefit where domestic supply, local registration, and price competitiveness influence purchasing decisions.

Sanofi announced in December 2024 that it would invest EUR 1 billion in an insulin production base in Beijing, its fourth production and supply base in China. The investment demonstrates that multinational participation in China increasingly requires local manufacturing and supply-chain capacity, not only imported branded products. Japan remains a high-value market supported by reimbursement and an aging population, while India, Australia, and South Korea present different combinations of patient growth, affordability constraints, domestic manufacturing, and digital-care readiness.

India's role extends beyond domestic demand because Biocon Biologics has expanded global biosimilar capabilities. Its November 2022 acquisition of Viatris' global biosimilars business provided commercial infrastructure and a portfolio of biosimilar products across advanced and emerging markets. This creates a pathway for Indian manufacturing capacity to affect competitive conditions beyond South Asia.

Latin America

Brazil is the region's largest insulin opportunity because its diabetes burden is large and public provision creates a substantial institutional purchasing role. IDF estimates identified more than 16 million adults with diabetes in Brazil in 2021, including approximately 7.7 million undiagnosed people. The commercial constraint is not only affordability; it is the ability to translate public coverage commitments into consistent diagnosis, procurement, distribution, and refill access.

Mexico and Argentina are important secondary markets where rising type 2 diabetes prevalence intersects with differing public-financing capacity. Suppliers must balance price competitiveness with reliable distribution and locally appropriate tender participation. Market growth can accelerate when diagnosis and reimbursement expand, but it can also be disrupted when public budgets or procurement cycles constrain supply.

Middle East and Africa

The Middle East and Africa combines high-prevalence Gulf markets with severe access gaps in parts of Africa. Saudi Arabia had an adult diabetes prevalence of 18.2% in 2021, projected to reach 24.3% by 2026. Saudi Arabia, the UAE, and other Gulf markets can support analog uptake through comparatively comprehensive healthcare funding, although public purchasing remains important.

Julphar has relevance in the Gulf through regional manufacturing and distribution capabilities. In South Africa and across other African markets, insulin demand is constrained by diagnostic capacity, affordability, cold-chain infrastructure, and public procurement funding. The region's clinical need is considerable, but revenue conversion depends on whether health systems can sustain availability of insulin and the consumables required for safe administration.

Saudi Arabia's projected rise from 18.2% diabetes prevalence in 2021 to 24.3% in 2026 illustrates a different challenge: high clinical need can support analog demand when funded access exists, but the commercial model remains tied to government purchasing and local distribution. The three dominant producers cannot apply one global playbook. Premium-device integration and contracted access matter most in North America; tender competitiveness and local supply matter more in China; and affordability, reliability, and channel reach are decisive across much of the Middle East, Africa, and Latin America.

Insulin Market Share & Competitive Landscape

Novo Nordisk, Eli Lilly, and Sanofi collectively account for more than 90% of global insulin market value. Their leadership is reinforced by worldwide regulatory portfolios, large-scale biologics manufacturing, established analog brands, and device compatibility. The competitive environment is nevertheless widening as biosimilar producers gain approvals and public purchasers prioritize lower-cost alternatives.

Adocia is developing differentiated insulin formulations through its BioChaperone platform. Its collaboration with Tonghua Dongbao on BioChaperone Lispro reflects the importance of local partnerships for innovation commercialization in China.

Biocon participates through Biocon Biologics, whose acquisition of Viatris' global biosimilars business expanded its commercial infrastructure and biosimilar portfolio.

Boehringer Ingelheim International participates in the insulin ecosystem through its collaboration with Eli Lilly, including work related to insulin glargine products.

Eli Lilly and Company is a leading global producer of human insulin, rapid-acting insulin, and insulin glargine products. Its 2023 list-price reductions demonstrate how access pressures are changing originator pricing strategy.

Gan & Lee Pharmaceuticals is a major Chinese insulin manufacturer with capabilities spanning recombinant human insulin and insulin analogs. Its domestic position is relevant to tender-based competition and lower-cost analog supply.

Gland Pharma participates through sterile injectable manufacturing capabilities that support the broader injectable and biosimilar supply base.

Recent Industry Developments

December 2024 — Adocia and Tonghua Dongbao completed final dosing in a Phase 3 study.

Adocia and Tonghua Dongbao announced that the final patient had been dosed in the Phase 3 clinical study of BioChaperone Lispro in China. The milestone was associated with a USD 10 million payment to Adocia.

February 2025 — FDA approved Merilog.

The FDA approved Merilog, insulin-aspart-szjj, as the first rapid-acting insulin biosimilar in the U.S. Merilog is approved as biosimilar to NovoLog and is available in prefilled pen and multiple-dose vial presentations.